Pamplona Capital Management (Pamplona) is pleased to announce it has agreed to acquire MedAssets (NASDAQ:MDAS), a leading healthcare performance improvement company that serves four out of every five hospitals in the United States. In addition, Pamplona has entered into a separate agreement with VHA-UHC Alliance NewCo, Inc. (VHA-UHC Alliance), the nation’s largest member-owned healthcare company, to divest MedAssets’ Spend and Clinical Resource Management (SCM) segment to VHA-UHC Alliance following the completion of Pamplona’s acquisition of MedAssets. “This is a major step in delivering on our vision of expanding Precyse beyond our traditional offerings into other areas that positively impact providers’ clinical and financial outcomes, both in Health Information Management and beyond and exactly why Precyse partnered with Pamplona earlier this year” Tweet this Pamplona will combine MedAssets’ Revenue Cycle Management (RCM) segment, which currently serves more than 2,700 hospital clients and touches more than $450 billion in gross patient revenue annually, with Precyse, a Pamplona-owned company that is a leader in health information management (HIM) services, technology, and education. MedAssets and Precyse already have a strategic partnership and share a number of customers, and their offerings are highly complementary. This combined enterprise will offer an end-to-end RCM and HIM solution and will be ideally positioned to partner with health systems to meet the needs of an evolving reimbursement environment which is increasingly requiring outsourced and clinically-integrated revenue cycle solutions. In addition to the sale of MedAssets’ SCM business to VHA-UHC Alliance, Pamplona and VHA-UHC have agreed to work together in select service offerings to serve their mutual members and customers, representing further strategic growth opportunities for both businesses. Pamplona is purchasing MedAssets for $31.35 per share, which represents a total enterprise value of approximately $2.7 billion for the acquisition. The transaction will require the receipt of customary approvals, including certain regulatory approvals and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction also is subject to customary closing conditions, including the approval of the merger agreement by MedAssets stockholders.